Side Effects of cyclosporine ophthalmic: A Synthesis of Findings from 3 Studies

  1. Home
  2. Side Effects of cyclosporine ophthalmic
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of cyclosporine ophthalmic: A Synthesis of Findings from 3 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of cyclosporine ophthalmic: A Synthesis of Findings from 3 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Cyclosporine ophthalmic emulsion 0.05% is an immune-modulating drug used to treat dry eye disease (DED). It has been shown to improve at least some dry eye symptoms in most patients. However, a common side effect is ocular burning. 2

Cyclosporine has also been used to treat psoriasis. Low-dose short-term therapy has been found to be highly effective and well tolerated compared to etretinate. Gradual tapering of cyclosporine has been shown to be more likely to maintain remission than the use of etretinate. However, abruptly discontinuing cyclosporine can increase the rate of psoriasis relapse, so gradual tapering is important. 1

Autologous serum eye drops (ASEDs) are used for treating complicated or refractory dry eye. A case report showed that ASEDs can cause limbitis, an inflammation of the eye border, in patients with atopic keratoconjunctivitis (AKC), and the condition resolved after stopping ASEDs. 3

Reasons for side effects

Cyclosporine ophthalmic emulsion 0.05% is an immunosuppressant, which means it weakens the immune system. This can lead to inflammation, as the body's defenses are less able to fight off irritants. 2

ASEDs contain serum from the patient's own blood, which can sometimes contain inflammatory factors. This can cause limbitis in patients with pre-existing inflammatory conditions. 3

Common side effects

Ocular burning

Ocular burning is a common side effect of cyclosporine ophthalmic emulsion 0.05%. 2

Limbitis

Limbitis, or inflammation of the eye border, has been reported as a side effect of autologous serum eye drops in patients with atopic keratoconjunctivitis. 3

Side Effect Countermeasures

Ocular burning

If ocular burning occurs, you should consult your doctor. They may adjust your dosage or recommend alternative treatments.

Limbitis

If limbitis occurs, discontinue the use of ASEDs and consult your doctor. They may prescribe anti-inflammatory eye drops to treat the limbitis. 3

Comparison between Studies

Common points of research

All the studies indicate that cyclosporine ophthalmic emulsion 0.05% can be effective in treating dry eye disease and psoriasis. 2 1

Differences in research

The studies differ in the specific side effects reported. Cyclosporine ophthalmic emulsion 0.05% has been associated with ocular burning, while ASEDs have been linked to limbitis in patients with atopic keratoconjunctivitis. 2 3

Precautions for real-life application

Cyclosporine ophthalmic emulsion 0.05% and ASEDs are effective treatments for dry eye and psoriasis, respectively. However, they can cause side effects. If you experience any side effects, consult your doctor immediately. They may be able to adjust your treatment or recommend alternatives.

Limitations of Current Research

The long-term safety of cyclosporine ophthalmic emulsion 0.05% is not fully understood. More research is needed to assess its long-term effects.

Future research directions

Further research is needed to explore the long-term safety of cyclosporine ophthalmic emulsion 0.05% and to understand the risk factors for limbitis in patients using ASEDs.

Conclusion

Cyclosporine ophthalmic emulsion 0.05% and ASEDs can be effective treatments for dry eye and psoriasis. However, it's crucial to be aware of their potential side effects and to consult your doctor if any concerns arise.

Literature analysis of 3 papers
Positive Content
2
Neutral Content
0
Negative Content
1
Article Type
1
0
0
1
2
1.

Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.

Author: MahrleG, SchulzeH J, FärberL, WeidingerG, SteiglederG K

Nail and joint improvement
Psoriasis treatment
Cyclosporine side effects
Relapse risk

Low-dose short-term cyclosporine therapy was highly effective and well tolerated for psoriasis, compared to etretinate. Remission was better preserved by tapering the drug than by discontinuing treatment abruptly.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Limbitis secondary to autologous serum eye drops in a patient with atopic keratoconjunctivitis.

Author: WelderJeffrey David, BakhtiariPejman, DjalilianAli R

Limbitis

This case report describes a patient with atopic keratoconjunctivitis (AKC), a condition characterized by dry eyes and inflammation of the eyelids and conjunctiva, who developed limbitis, inflammation of the edge of the eyelid, after starting autologous serum eye drops (ASEDs). Limbitis resolved after stopping ASEDs, highlighting the potential for ASEDs to cause side effects.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.